FibroBiologics (FBLG) Proxy filing summary

Executive summary

• Special Meeting scheduled for September 17, 2026, to approve the issuance of up to 8,163,266 shares of common stock under a Securities Purchase Agreement (SPA) and up to 285,714 shares under an Engagement Letter, both related to outstanding warrants.

• The issuance is required to comply with Nasdaq Listing Rule 5635(d), which mandates shareholder approval for certain stock issuances exceeding 20% of outstanding shares or voting power.

• Failure to approve could result in financial penalties and liquidity issues, as the company may be required to pay liquidated damages or seek emergency financing.

• The Board recommends voting in favor, citing the company's cash position and liquidity needs, with proceeds intended for working capital and general corporate purposes.

Voting matters and shareholder proposals

• Only one proposal is up for vote: approval of the stock issuance under the SPA and Engagement Letter.

• The Board unanimously recommends a FOR vote; abstentions and broker non-votes will not affect the outcome.

• Stockholder proposals for the 2027 annual meeting must comply with SEC and company bylaw deadlines, with specific dates and requirements outlined.

Board of directors and corporate governance

• Pete O'Heeron serves as founder, CEO, and Chairperson, holding all 125 shares of Series C Preferred Stock with super voting rights.

• The Series C Preferred Stock is subject to an irrevocable proxy in favor of the Board, ensuring Board control over its votes except on matters affecting O'Heeron's rights.

• The Board will exercise 1,625,000 votes (21% of total) FOR the proposal using the Series C Preferred Stock.